The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
The U.S. Food and Drug Administration approved a new non-opioid pain medication developed by the Massachusetts-based company ...
Federal officials on Thursday approved a new type of pain drug designed to eliminate the risks of addiction and overdose ...
PROVIDENCE — Kin Southern Table & Bar, a popular restaurant in downtown, has permanently closed. The 50-seat restaurant was located on the ground floor of the Biltmore Garage on Washington ...
Shares of Vertex Pharmaceuticals Inc. VRTX slipped 1.72% to $416.96 Thursday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index SPX falling 0.21 ...
PROVIDENCE, R.I. (WPRI) — The Rhode Island State Police have fired two troopers who posted a video on social media of 21-year-old Alex Montesino getting hit and killed by a car on I-95 in October.
Vertex Pharmaceuticals (NASDAQ: VRTX) is a biotechnology company with a strong track record of success in developing treatments for cystic fibrosis (CF). Vertex is strategically expanding into the ...
It usually doesn't matter if you buy a given stock immediately or two weeks later. Sure, the stock could move up or down but typically not enough to matter all that much. However, there are ...
The most recent trading session ended with Vertex Pharmaceuticals (VRTX) standing at $416.96, reflecting a -1.72% shift from the previouse trading day's closing. The stock's performance was behind ...
In a court filing on Monday, the Department of Health and Human Services fired back at Vertex Pharmaceuticals, standing by a directive that the biotech’s proposed fertility services program to go with ...
Shares of Vertex Pharmaceuticals Inc. VRTX advanced 3.06% to $424.26 Wednesday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index SPX rising ...
Vertex Pharmaceuticals (VRTX) comes in second with a score of 4.04 and a Buy rating given its dominance in the cystic fibrosis treatment category and diversified pipeline, making a compelling case ...